Anemia of Chronic Renal Failure
Understand Anemia of Chronic Renal Failure (also called Anemia in Chronic Kidney Disease or Renal Anemia). This resource provides information on diagnosis, clinical documentation, and medical coding for Anemia of Chronic Renal Failure in chronic kidney disease patients. Learn about healthcare best practices for managing and documenting renal anemia for accurate medical coding and improved patient care.
Decreased red blood cell production due to impaired kidney function.
Fatigue, weakness, shortness of breath, pale skin, dizziness.
Chronic kidney disease stages 3-5, dialysis clinics, nephrology.
ICD-10 Code Families
Complete code families applicable to D63.1
When to use each related code
| Description | When to use |
|---|---|
| Low red blood cells due to kidney failure. | Document when anemia is caused by decreased erythropoietin production in chronic kidney disease. |
| Low iron levels in the blood. | Code when iron deficiency is the primary cause of anemia, may coexist with renal anemia. Consider testing ferritin and transferrin saturation. |
| Vitamin B12 deficiency leading to anemia. | Use this code when B12 deficiency is the primary cause of anemia. May occur in patients with renal disease due to dietary restrictions or malabsorption. |
Best-practice checklist
- ✓Document GFR and staging of chronic kidney disease.
- ✓Specify anemia type (e.g., normocytic, normochromic).
- ✓Hgb/Hct levels and dates.
- ✓Iron studies (ferritin, transferrin saturation, TIBC).
- ✓EPO level (if measured).
Common pitfalls to avoid
Coding anemia without specifying the type (e.g., normocytic, normochromic) may lead to claim denials or inaccurate DRG assignment. Important for CDI and medical coding accuracy.
Failing to document the stage of chronic kidney disease impacts risk adjustment and reimbursement. Crucial for healthcare compliance and medical coding audits.
Overlooking other conditions related to renal anemia, such as iron deficiency or erythropoietin deficiency, can affect coding and quality metrics. Important for CDI specialists.
Best-practice tips
- 01Optimize EPO dosing with Hb monitoring (ICD-10 T85.81XA).
- 02Document iron studies for accurate coding (N79.0, Z01.89).
- 03Assess for underlying causes, code precisely (ICD-10-CM D63.1).
- 04Ensure proper ESA justification for compliance (N18.5).
- 05Monitor for adverse effects, document thoroughly.
Step-by-step checklist
- 1
Confirm eGFR <60 mL/min/1.73 m2 (CKD stage 3 or higher)
- 2
Verify Hb <13.5 g/dL (men) or <12 g/dL (women)
- 3
Exclude other anemia causes (iron, B12, folate deficiency)
- 4
Document CKD stage, Hb level, iron studies
Ready-to-paste narrative
Patient presents with symptoms consistent with anemia of chronic renal failure (also known as anemia in chronic kidney disease or renal anemia). The patient's chronic kidney disease (CKD) stage [Insert CKD stage, e.g., Stage 3, Stage 4, Stage 5] is documented, and laboratory results demonstrate a decreased hemoglobin level of [Insert Hb level, e.g., 9.5 g/dL] and a reduced hematocrit of [Insert Hct, e.g., 28%]. These findings meet the diagnostic criteria for renal anemia secondary to impaired erythropoietin production by the kidneys. Symptoms reported include fatigue, weakness, shortness of breath on exertion, and pallor. Differential diagnoses considered include iron deficiency anemia, vitamin B12 deficiency anemia, and anemia of chronic inflammation. Iron studies, including ferritin and transferrin saturation, have been ordered to evaluate for iron deficiency. Vitamin B12 levels have also been assessed. The patient's current medications include [List current medications]. Treatment plan includes monitoring hemoglobin and hematocrit levels, considering erythropoiesis-stimulating agents (ESAs) such as epoetin alfa or darbepoetin alfa, and iron supplementation if indicated. Patient education provided regarding the importance of medication adherence, dietary considerations, and regular follow-up appointments to optimize management of renal anemia and chronic kidney disease progression. ICD-10 code D63.1 is applied for anemia in chronic kidney disease. This documentation supports medical necessity for prescribed treatments and facilitates accurate medical billing and coding.
Common questions and answers
What are the best evidence-based treatment strategies for anemia of chronic renal failure in non-dialysis patients?+
Managing anemia in chronic kidney disease (CKD) not yet requiring dialysis often involves a multi-pronged approach. The cornerstone of treatment typically includes oral iron supplementation to address iron deficiency, a common contributing factor. Explore how intravenous iron therapy can be beneficial if oral iron is ineffective or poorly tolerated, especially when transferrin saturation (TSAT) is low (<20%) and ferritin is <500 ng/mL. Erythropoiesis-stimulating agents (ESAs) like epoetin alfa or darbepoetin alfa are frequently prescribed to stimulate red blood cell production. Consider implementing a patient-specific ESA dosing strategy while closely monitoring hemoglobin levels to avoid overshooting targets and minimize potential adverse events. Furthermore, addressing underlying causes of anemia, such as nutritional deficiencies and inflammation, is crucial for optimal management. Learn more about optimizing ESA and iron therapy based on the latest KDIGO guidelines.
How do I effectively differentiate between anemia of chronic renal failure and other anemia types in a patient with chronic kidney disease?+
Distinguishing anemia of chronic kidney disease (CKD), also known as renal anemia, from other forms of anemia requires a comprehensive evaluation. A key feature of renal anemia is its association with decreased erythropoietin (EPO) production by the failing kidneys. Clinically, this presents as a normocytic, normochromic anemia. Explore laboratory findings including a low hemoglobin level, reduced reticulocyte count, and normal or slightly decreased mean corpuscular volume (MCV). Consider evaluating serum creatinine, estimated glomerular filtration rate (eGFR), and transferrin saturation (TSAT) to assess kidney function and iron status. While other anemias can coexist with CKD, such as iron deficiency anemia or anemia of chronic inflammation, renal anemia is primarily driven by impaired EPO production. Differentiating these types is vital for targeted treatment. Learn more about the role of bone marrow biopsy in complex cases to assess erythropoietic activity.
What are the latest KDIGO guidelines for managing hemoglobin targets and iron parameters in anemia of chronic renal failure?+
The Kidney Disease Improving Global Outcomes (KDIGO) guidelines offer evidence-based recommendations for managing anemia in chronic kidney disease. They generally do not recommend administering ESAs to patients with non-dialysis dependent CKD with hemoglobin values greater than 10 g/dL due to increased risks associated with higher hemoglobin targets, except in cases of severe, symptomatic anemia. For iron therapy, the KDIGO guidelines suggest maintaining a TSAT target of 20-50% and a ferritin level between 100-500 ng/mL. Consider implementing these recommendations and tailoring treatment to individual patient characteristics. Furthermore, regularly monitor hemoglobin, iron status, and adverse events related to ESA or iron therapy. Explore how optimizing management based on these guidelines can improve patient outcomes and minimize risks.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.